Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
123
resultados
Última actualización
06/08/2025 [06:55:00]
Resultados 75 a 100 de 123
Resumen de: US2024316183A1
The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the S1 subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.
Resumen de: US2025207140A1
Provided herein, inter alia, are compositions comprising nucleic acid compounds and methods of using the compositions for the prevention and treatment of respiratory diseases, including SARS-CoV-2 infections.
Resumen de: US2025205268A1
Therapies comprising administering at least one antiviral nucleoside, and the use of such therapies in the treatment of viral infections, such as infection by Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, orthomyxoviridae virus, paramyxoviridae virus, RSV, influenza A virus, influenza B virus, filoviridae virus, human coronavirus, SARS-CoV-1, MERS-CoV, SARS-CoV-2, Ebola virus, or Zika virus, are disclosed herein.
Resumen de: US2025206754A1
A chemical compound 2-({6-phenylthieno2,3-dpyrimidin-4-yl}oxy)benzamide for use as a CCR7 (C-C chemokine receptor type 7) antagonist. It is also a pan-chemokine antagonist and has an antagonistic effect to CCR1, CCR2, CCR3, CCR5, CCR9 and CXCR4 chemokine receptors for use in the prevention of metastatsis formation in lung, liver and ribs in in vivo mice breast cancer model. Also described are chemical compounds 3-chloro-2-{6-(2-chlorophenyl)-2,5-dimethylthieno2,3-dpyrimidin-4-yloxy}benzamide and 3-chloro-2-{6-(2-chlorophenyl)-2-methylthieno2,3-dpyrimidin-4-yloxy}benzamide, as pan-chemokine antagonists. These compounds are for use in the prevention or treatment of: (i) diseases associated with chemokine receiptors which are, specifically, lung, liver, ribs and lymph node metastasis and the progression of many different malignancies such as breast, gastric, skin (melanoma), head and neck, lung, esophageal, hepatocellular, cervical, thyroid, tonsillar, colorectal and prostate cancers; (ii) virus infection diseases associated with chemokine receptors such as HIV-1, HIV-2, SARS-CoV-2 (COVID-19); and (iii) the immune related diseases such as psoriasis, arthritis and atopic demiatitis.
Resumen de: WO2025135605A1
Disclosed are peptides, nucleic acids, recombinant expression vectors, cells, a SARS-CoV-2 vaccine substance, a SARS-CoV vaccine composition, and a SARS-CoV-2 immunization method.
Resumen de: WO2025137577A1
Provided herein are short viral RNA (svRNA) and human RNA sequences that exhibit modulated expression during viral infection and are therefore useful for detecting viral infections. Further disclosed herein are compositions, methods, and kits for detecting and treating infections, including early-stage and latent infections with low viral titers. In certain embodiments the compositions, methods, and kits for detecting and treating infections include detecting in a sample from a subject 10-50 nucleotide length short viral RNA (svRNA), modulated expression of 10-50 nucleotide length RNA in the subject, or a combination thereof, thereby detecting infection by a virus in the subject.
Resumen de: WO2025137448A1
The present disclosure relates to coronavirus vaccines and methods for use thereof.
Resumen de: US2025186576A1
The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the SI subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.
Resumen de: US2025205178A1
SARS-CoV-2 has caused a global pandemic with significant humanity and economic loss since the beginning of 2020. Flaviviruses such as Zika and Dengue viruses are also significant human pathogens. Although SARS-CoV-2 vaccines are effective in preventing severe disease outcomes, they are less effective in controlling infection or re-infection, particularly due to rapid evolution of viral variants of SARS-CoV-2. Currently only limited options are available to treat SARS-CoV-2 and flavivirus infections for vulnerable populations. Potential of a future pandemic of other viruses is high. The present invention features compositions and methods for a universal high throughput screening (HTS) assay to identify inhibitors targeting the S-adenosyl-L-methionine (SAM)-binding site of viral methyltransferases (MTases) using SAM as a methyl donor.
Resumen de: US2025205273A1
The present invention relates to a composition comprising at least chitosan and xanthohumolone, to a process for preparing same and to the uses thereof. More particularly, the invention relates to a composition comprising at least chitosan and xanthohumolone for use as an antiviral composition, in particular in the treatment or prevention of COVID-19.
Resumen de: WO2025137284A2
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.
Resumen de: AU2023326053A1
Described herein are methods and related compositions for determining the likelihood of neurological post-acute sequelae of COVID-19 (NP ASC) in a subject based on the levels of biomarkers in a combination of biomarkers from a biological sample from the subject. Also disclosed herein are methods for treating a subject identified as having a high likelihood of suffering from NP ASC and treating the subject by modulating the level or activity of an NPASC therapeutic target identified herein.
Resumen de: ZA202401786B
Disclosed is a method for treating a subject that has previously been infected with SARS-CoV-2 and exhibiting at least one Post COVID- 19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.
Resumen de: GB2636672A
A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.
Resumen de: KR20220166497A
The present invention relates to a composition containing a Schisandra chinensis extract as an active ingredient for preventing or treating coronavirus infection-19 (COVID-19). The Schisandra chinensis extract according to the present invention was confirmed to suppress invasion of inflammatory cells in alveoli, to reduce expression of ACE2, which is an RBD receptor, and p-STAT3 and IL-6, which are inflammation-related factors, to suppress phosphorylation of JNK, ERK, p38, IκB, and NFκB in an inflammatory signal transduction pathway, and to increase the expression of Nrf2 and NQO-1, which are antioxidant factors, in a respiratory disease mouse induced by a receptor-binding domain (RBD), which is a protein constituting a spike of SARS-CoV-2. Accordingly, it can be usefully used in related industries.
Resumen de: WO2025127420A1
The present invention relates to engineered human antibodies having neutralizing activity against human coronavirus and use thereof. The novel human antibodies against coronavirus, of the present invention, specifically bind to SARS-CoV-1, SARS-CoV-2, or a variant thereof, exhibit neutralizing activity against SARS-CoV-1, SARS-CoV-2, or a variant thereof, and have cross-reactivity, and thus can be used for the prevention or treatment of coronavirus infection. In addition, the antibodies and fragments having immunological activities thereof can be used to rapidly detect various types of coronaviruses, and thus can be used for the immunodiagnosis of human coronaviruses, particularly SARS-CoV-2 with high infectivity, and variants thereof.
Resumen de: AU2023378779A1
The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.
Resumen de: US2025195557A1
An objective of the present invention is to provide a nonpharmaceutical anti-human coronavirus composition that prevents human coronavirus infections, the onset of the infections, or aggravation of symptoms of the infections. The anti-human coronavirus composition according to the present invention includes an exopolysaccharide produced by a lactic acid bacterium in genus Lactobacillus as an active component. The lactic acid bacterium in the genus Lactobacillus may belong to a Lactobacillus delbrueckii species. The lactic acid bacterium in the genus Lactobacillus may specifically be Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).
Resumen de: WO2025127075A1
The problem addressed is to provide surface-modified iron oxide nanoparticles for use in a vaccine exhibiting an infection preventive effect on SARS-CoV-2. The problem can be solved by surface-modified iron oxide nanoparticles comprising SARS-CoV-2 spike protein and iron oxide nanoparticles, where the spike protein of SARS-CoV-2 is bound to the surface of the iron oxide nanoparticles.
Resumen de: WO2025127420A1
The present invention relates to engineered human antibodies having neutralizing activity against human coronavirus and use thereof. The novel human antibodies against coronavirus, of the present invention, specifically bind to SARS-CoV-1, SARS-CoV-2, or a variant thereof, exhibit neutralizing activity against SARS-CoV-1, SARS-CoV-2, or a variant thereof, and have cross-reactivity, and thus can be used for the prevention or treatment of coronavirus infection. In addition, the antibodies and fragments having immunological activities thereof can be used to rapidly detect various types of coronaviruses, and thus can be used for the immunodiagnosis of human coronaviruses, particularly SARS-CoV-2 with high infectivity, and variants thereof.
Resumen de: US2025195639A1
In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.
Resumen de: US2025195464A1
Provided herein are Alotaketal compounds and derivatives thereof that have antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (1), (2) and (3), for use as antiviral agents in the treatment or prevention of coronavirus infection. Methods for using the compounds in the treatment or prophylaxis of a coronavirus infection are provided. In particular, the coronavirus infection may selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus-1 (SARS-C0V-1) infection; SARS coronavirus-2 (SARS-C0V-2) infection; and Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) infection. More specifically, the coronavirus infection may be a human coronavirus 229E (HC0V-229E) infection.
Resumen de: US2025201406A1
Method for predicting severity of COVID-19 disease resulting from infection with SARS-COV-2 (severe acute respiratory syndrome coronavirus 2). The method uses a high dimensional approach to construct a comprehensive metabolic landscape of immune cells participating in the anti-viral response against SARS-CoV-2. Also encompassed within the invention are novel immune cell subsets exhibiting metabolic dysfunction that could serve as predictive biomarkers for COVID-19 severity or as targets for therapeutic interventions in COVID-19 disease.
Resumen de: WO2025128200A1
Disclosed is a method of treating lung injury in a patient comprising providing a therapeutically effective amount of a pharmaceutical agent that enhances peroxisome biogenesis to a patient. The method includes increasing the number of peroxisomes in alveolar macrophages, decreasing peroxisome degradation, and improving peroxisome function in alveolar macrophages. Increasing the number and function of peroxisomes in alveolar macrophages promotes healing of lung injury and regeneration of alveolar epithelial. The lung injury may be due to infection, including viral infection, such as SARS-CoV-2 infection or influenza infection. The lung injury may also be due to exposure to caustic substances, tobacco smoke, asbestos, or fine particulate matter.
Nº publicación: WO2025125852A1 19/06/2025
Solicitante:
ABDALI NARGESS [IR]
ABDALI, Nargess
Resumen de: WO2025125852A1
An oral vaccine for COVID-19 is disclosed. The oral vaccine for COVID-19 includes a delivery platform including Arthrospira platensis with a plurality of host genomes and a plurality of COVID-19 antigen delivery vectors coupled to the plurality of host genomes. Each respective host genome of the plurality of host genomes includes a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 1. Each COVID-19 antigen delivery vector of the plurality of COVID- 19 antigen delivery vectors has a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 2. Each respective COVID-19 antigen delivery vector of the plurality of COVID-19 antigen delivery vectors includes at least one antigen of COVID-19 with a weight ratio of the delivery platform to the at least one antigen of COVID-19in a range of 1: 10-3 to 1: 2.5 × 10-3 (delivery platform: at least one antigen of COVID-19).
BOPI
Sede Electrónica
